S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
66,000% upside on tiny biotech? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
66,000% upside on tiny biotech? (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
How You Can Reverse Engineer Michael Burry's Latest Buy
NASDAQ:PTGX

Protagonist Therapeutics (PTGX) Stock Forecast, Price & News

$17.57
+0.08 (+0.46%)
(As of 09/27/2023 ET)
Compare
Today's Range
$17.24
$17.78
50-Day Range
$16.98
$20.37
52-Week Range
$7.24
$30.10
Volume
406,299 shs
Average Volume
648,547 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

Protagonist Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
110.6% Upside
$37.00 Price Target
Short Interest
Healthy
4.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Protagonist Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.35) to ($2.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

631st out of 976 stocks

Pharmaceutical Preparations Industry

301st out of 455 stocks


PTGX stock logo

About Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Price History

PTGX Stock News Headlines

30 Days of MarketBeat All Access Free
Access our premier stock research platform that includes research tools, stock screeners, instant alerts, real-time news and much more.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
PTGX - Protagonist Therapeutics, Inc.
See More Headlines
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Company Calendar

Last Earnings
8/03/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+110.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-127,390,000.00
Pretax Margin
-16,319.91%

Debt

Sales & Book Value

Annual Sales
$26.58 million
Book Value
$4.38 per share

Miscellaneous

Free Float
54,654,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
1.86
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Dinesh V. Patel Ph.D. (Age 66)
    CEO, Pres, Sec. & Director
    Comp: $883.46k
  • Dr. Suneel K. Gupta Ph.D. (Age 65)
    Chief Devel. Officer
    Comp: $640.89k
  • Dr. Mark Smythe Ph.D. (Age 58)
    Founder & VP Technology
  • Mr. Asif Ali (Age 49)
    Exec. VP & Chief Financial Officer
  • Mr. Mohammad Masjedizadeh Ph.D.
    Exec. VP & Chief Technical Officer
  • Mr. Matthew M. Gosling (Age 52)
    Exec. VP & Gen. Counsel
  • Ms. Carena Spivey
    Sr. VP of HR
  • Dr. Ashok Bhandari Ph.D. (Age 59)
    Exec. VP & Chief Drug Discovery and Preclinical Devel. Officer
  • Dr. Scott Eric Plevy M.D.
    Exec. VP & Therapeutic Head of Gastroenterology
  • Mr. Carter J. King (Age 52)
    Sr. VP of Bus. Devel.













PTGX Stock - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year target prices for Protagonist Therapeutics' stock. Their PTGX share price forecasts range from $34.00 to $41.00. On average, they predict the company's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 110.6% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2023?

Protagonist Therapeutics' stock was trading at $10.91 on January 1st, 2023. Since then, PTGX shares have increased by 61.0% and is now trading at $17.57.
View the best growth stocks for 2023 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.03.

What ETF holds Protagonist Therapeutics' stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.71%), State Street Corp (6.17%), Cowen AND Company LLC (2.90%), Cormorant Asset Management LP (2.61%), Perceptive Advisors LLC (2.55%) and Geode Capital Management LLC (1.87%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $17.57.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $1.01 billion and generates $26.58 million in revenue each year. The company earns $-127,390,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

The company employs 106 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.

This page (NASDAQ:PTGX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -